VX-702 is a selective p38 MAP kinase inhibitor that has been investigated for its potential therapeutic applications in the treatment of inflammatory diseases, particularly rheumatoid arthritis. It plays a crucial role in regulating the production of pro-inflammatory cytokines such as TNF-alpha and IL-1 beta. By inhibiting p38 MAP kinase, VX-702 was developed to reduce inflammation and alleviate symptoms in patients with autoimmune conditions involving excessive inflammation. Although its clinical development was discontinued after Phase II trials, it remains a valuable research tool for studying inflammatory pathways and targeted therapies.